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Abstract:  Mammalian  genomes  encode  genes  for  more  than  30  phospholipase  A2s 
(PLA2s) or related enzymes, which are subdivided into several subgroups based on their 
structures, catalytic mechanisms, localizations and evolutionary relationships. More than 
one third of the PLA2 enzymes belong to the secreted PLA2 (sPLA2) family, which consists 
of low-molecular-weight, Ca
2+-requiring extracellular enzymes, with a His-Asp catalytic 
dyad.  Individual  sPLA2  isoforms  exhibit  unique  tissue  and  cellular  localizations  and 
enzymatic  properties,  suggesting  their  distinct  pathophysiological  roles.  Recent  studies 
using  transgenic  and  knockout  mice  for  several  sPLA2  isoforms,  in  combination  with 
lipidomics  approaches,  have  revealed  their  distinct  contributions  to  various  biological 
events.  Herein,  we  will  describe  several  examples  of  sPLA2-mediated  phospholipid 
metabolism in vivo, as revealed by integrated analysis of sPLA2 transgenic/knockout mice 
and lipid mass spectrometry. Knowledge obtained from this approach greatly contributes to 
expanding our understanding of the sPLA2 biology and pathophysiology. 
Keywords:  phospholipase  A2;  phospholipid;  lipidomics;  transgenic  mouse; 
knockout mouse 
Abbreviations: PLA2, phospholipase A2; sPLA2, secreted PLA2; cPLA2, cytosolic PLA2; 
iPLA2,  Ca
2+-independent  PLA2;  Tg,  transgenic;  ARDS,  acute  respiratory  distress 
syndrome; BALF, bronchoalveolar fluid; LPS, lipopolysaccharide; ESI-MS, electrospray 
ionization  mass  spectrometry;  PC,  phosphatidylcholine;  LPC,  lysophosphatidylcholine; 
PG,  phosphatidylglycerol;  PE,  phosphatidylethanolamine;  PS,  phosphatidylserine;  
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LDL,  low-density  lipoprotein;  HDL,  high-density  lipoprotein;  VLDL,  very  low-density 
lipoprotein; ABC, ATP-binding cassette; PGD2, prostaglandin D2; PGE2, prostaglandin E2; 
LTB4,  leukotriene  B4;  PUFA,  polyunsaturated  fatty  acid;  DHA,  docosahexaenoic  acid; 
DPA,  docosapentaenoic  acid;  LXR,  liver  X  receptor;  PPAR,  peroxisome  proliferator-
activated  receptor;  StAR,  steroidogenic  acute  regulatory  protein;  DRG,  dorsal  root 
ganglion; COX, cyclooxygenase; LOX, lipoxygenase; CYP450, cytochrome P450; HPLC, 
high performance liquid chromatography; WT, wild-type. 
 
1. Introduction  
Phospholipase A2 (PLA2) hydrolyzes the sn-2 position of glycerophospholipids to yield fatty acids 
and lysophospholipids. In the view of signal transduction, the PLA2 reaction has been considered to be 
of  particular  importance  since  arachidonic  acid,  one  of  the  polyunsaturated  fatty  acids  (PUFAs) 
released by PLA2, is metabolized to various lipid mediators such as prostaglandins and leukotrienes. In 
addition,  lysophospholipids  or  its  metabolites,  such  as  lysophosphatidic  acid  and  platelet-activating 
factor, also represent another class of lipid mediators. These lipid mediators exert numerous biological 
actions through their cognate G protein-coupled receptors on target cells. PLA2 has also been implicated 
in membrane glycerophospholipid remodeling, thereby contributing to cellular homeostasis. 
Mammalian genomes encode more than 30 PLA2s or related enzymes, which are classified into 
several subgroups on the basis of their primary structures and functions. Critical contributions of the 
intracellular PLA2 families, namely cytosolic PLA2s (cPLA2s) and Ca
2+-independent PLA2s (iPLA2s), 
to aracidnonic acid metabolism and membrane homeostasis, respectively, have been well established 
by  numerous  studies  [1,2].  The  secreted  PLA2  (sPLA2)  family  represents  structurally  related,  
disulfide-rich, low molecular weight, lipolytic enzymes with a His-Asp catalytic dyad. sPLA2s occur in a 
wide variety of vertebrate and invertebrate animals, plants, fungus, bacteria, and viruses, and 11 sPLA2 
isozymes (IB, IIA, IIC, IID, IIE, IIF, III, V, X, XIIA and XIIB) have been identified in mammals [2–4]. 
Of these, sPLA2s belonging to the group I/II/V/X collection (conventional sPLA2s) are closely related,  
14–19-kDa secreted enzymes with a highly conserved Ca
2+-binding loop (XCGXGG) and a catalytic 
site (DXCCXXHD). In addition to these elements, there are six absolutely conserved disulfide bonds 
and up to two additional unique disulfide bonds, which contribute to the high degree of stability of 
these enzymes. Group III and group XII sPLA2s (atypical sPLA2s) share homology with the I/II/V/X 
collection of sPLA2s only in the Ca
2+-binding loop and catalytic site, thereby representing the group III 
and XII collections, respectively. sPLA2 enzymes hydrolyze the ester bond at the sn-2 position of 
glycerophospholipids with distinct selectivity toward sn-2 fatty acids and polar head groups in the 
presence  of  mM  concentrations  of  Ca
2+.  Since  individual  sPLA2s  display  distinct  cellular/tissue 
distributions and substrate head group specificities, they may play non-redundant, isoform-specific 
roles in vivo.  
Although many potential functions of sPLA2s have been proposed on the basis of in vitro studies, 
the precise biological roles and relevant target membranes of these enzymes in vivo have remained 
elusive  until  recently.  Several,  if  not  all,  sPLA2s  are  capable  of  releasing  arachidonic  acid  from Int. J. Mol. Sci. 2011, 12                       
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cultured cell membranes when overexpressed or added exogenously at excess amounts in vitro [2–4]. 
However, it still remains controversial whether this function could indeed be operated by sPLA2s 
in vivo.  The  reason  why  sPLA2s  are  secreted  is  most  probably  because  sPLA2s  participate  in 
pathophysiology  by  regulating  extracellular  phospholipid  metabolism,  which  include  adjacent  cell 
membranes (plasma membranes or microvesicles shed from cells), non-cellular lipid components such 
as lipoproteins and pulmonary surfactant, and foreign phospholipids such as microbe membranes and 
dietary lipids. The in vitro actions of individual sPLA2s on various target membranes are summarized 
in Table 1. This target variation may explain the molecular evolution of a number of sPLA2s with 
distinct  localizations  and  substrate  specificities.  Therefore,  once  some  phenotypes  appear  in  
sPLA2-knockout or -transgenic mice, this could be attributable to a combination of these varied actions 
rather than only by alterations in lipid mediator levels. 
In the past few years, we have analyzed the phenotypes of transgenic or knockout mice for several 
sPLA2 isozymes, in combination with a lipid profiling technique by mass spectrometry. This integrated 
approach, together with studies using these mice by other research groups, has helped us understand 
the potential action of a given sPLA2 on particular target membranes and its impact on pathophysiology 
in vivo. In this article, we will give an overview of current analyses on transgenic or knockout mice for 
two particular conventional sPLA2s, group V and X, and an atypical sPLA2, group III. Also, we will give 
a brief summary of pathophysiological functions of other sPLA2s that have been clarified to date. 
Table 1. In vitro actions of sPLA2s on various membranes. 
sPLA2s   
resting cell 
membrane 
activated cell 
membrane 
lipoprotein 
(PC) 
surfactant   
(PC) 
Gram-positive 
bacteria 
Gram-negative 
bacteria 
conventional sPLA2s  IB  weak  moderate  weak  weak  none  none 
  IIA  none  moderate  weak  weak  very high  weak* 
  IID  none  weak  n.d.  weak  high  none 
  IIE  none  weak  n.d.  n.d.  moderate  none 
  IIF  moderate  moderate  moderate  n.d.  none  none 
  V  high  very high  very high  very high  high  none 
  X  very high  very high  very high  high  moderate  none 
atypical sPLA2s  III  moderate  moderate  high  n.d.  n.d.  none 
  XIIA  none  none  n.d.  n.d.  high  moderate 
n.d.; not determined. sPLA2-IIC is not included since it is a pseudogene in human. 
*sPLA2-IIA kills Gram-negative bacteria only in the presence of bacterial permeability-increasing protein. 
For details, please see refs [30,31,41,47,55,79,85,94]. 
2. Biological Functions of sPLA2s in Vivo 
2.1. Group V sPLA2 (sPLA2-V)  
Among  the  conventional  sPLA2s,  sPLA2-V  has  the  simplest  structure.  It  lacks  group  I-  and  
II-specific  disulfide  bonds,  group  II-specific  C-terminal  extension,  and  group  I-  or  X-specific  
N-terminal propeptide [5]. However, sPLA2-V is evolutionally close to group II sPLA2s, since the Int. J. Mol. Sci. 2011, 12                       
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Pla2g5  gene  resides  within  the  gene  cluster  for  the  group  II  subfamily  of  sPLA2s.  sPLA2-V  is 
expressed at the highest level in the heart, followed by the lung. In the lung, sPLA2-V is expressed in 
the airway epithelium and alveolar macrophages, and its expression is markedly elevated in mice 
receiving models of asthma or acute respiratory distress syndrome (ARDS) [6]. Immunohistochemistry 
and in situ hybridization of sPLA2-V clearly indicate its location in the bronchial epithelium of patients 
with severe pneumonia [7].  
To assess the biological functions of sPLA2-V, we generated transgenic mice overexpressing this 
enzyme in the whole body (Pla2g5-Tg) [8]. We found that Pla2g5-Tg mice died in the neonatal period 
(within 8 h after birth) due to respiratory failure. The lungs of Pla2g5-Tg mice exhibited atelectasis 
with thickened alveolar walls and narrow air spaces, accompanied by infiltration of macrophages and 
only modest elevations in eicosanoid levels. This severe pulmonary defect in Pla2g5-Tg mice was 
attributable  to  marked  reduction  of  the  lung  surfactant  phospholipids,  phosphatidylcholine  (PC)  
(Figure  1a)  and  phosphatidylglycerol  (PG)  (Figure  1b),  as  demonstrated  by  ESI-MS  (electrospray 
ionization mass spectrometry) analysis.  
The principal function of lung surfactant, which is a mixture of phospholipids (90%) and surfactant 
proteins  (10%),  is  to  reduce  the  work  of  breathing  by  lowering  alveolar  surface  tension  during 
respiration.  PC  with  saturated  and  monosaturated  fatty  acids  (palmitic  acid  in  particular)  is 
predominant in surfactant phospholipids (~80% of total lipid) [9], and PG (~10% of total lipid) plays a 
role in phospholipid-protein interactions that maintain the alveolar surfactant layer, especially through 
interaction  with  the  surfactant  protein  SP-B  [10].  Since  changes  in  the  ratio  of  the  surfactant 
components can dramatically alter the surface tension in small airways and alveoli, compromising 
airway  patency,  gas  exchange  and  host  defense,  any  surfactant  abnormality  can  have  severe 
pathological consequences in terms of lung function. Indeed, previous studies have indicated a role of 
sPLA2s  in  inflammation-mediated  surfactant  malfunction  through  hydrolysis  of  surfactant 
phospholipids [11–18]. Aberrant hydrolysis of surfactant phospholipids leads to ARDS, which is a 
clinically and pathologically complex syndrome due to acute life-threatening lung injury involving an 
alteration of pulmonary surfactant, and numerous predisposing factors can be involved in the etiology, 
including pneumonia and sepsis [9]. Hydrolysis of surfactant phospholipids is an early pathological 
event of ARDS, and hydrolysis of as little as 10–15% of surfactant can cause this serious condition. 
Levels of sPLA2 activity in bronchoalveolar fluid (BALF) of patients with ARDS are often positively 
correlated with disease severity [11–14], and chemical sPLA2 inhibitors that block classical sPLA2s 
protect animals against experimental ARDS or related lung injury [15]. Given that the expression of 
sPLA2-V is greatly elevated in human lungs with severe inflammation [7] and in cultured human 
bronchial epithelial cells stimulated with pro-inflammatory cytokines (Figure 1c), that sPLA2-V can 
efficiently hydrolyze lung surfactant phospholipids in vitro [16,18], and that the neonatal death of 
Pla2g5-Tg mice is in many aspects similar to that observed in mutant mice manipulated for a panel of 
genes that have been implicated in surfactant homeostasis [19,20], sPLA2-V may contribute to ongoing 
surfactant hydrolysis often observed in the lungs of patients with ARDS (Figure 1d).  Int. J. Mol. Sci. 2011, 12                       
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Figure  1.  Pla2g5-Tg  mice  display  fatal  respiratory  failure  due  to  lung  surfactant 
destruction. (a and b) ESI-MS of surfactant PC (a) and PG (b) from Pla2g5-Tg mice (right) 
and WT mice (left); Molecular peaks shown in red, such as PC32:0 (16:0-16:0) and PC32:1 
(16:0-16:1) (a) as well as PG32:0 (16:0-16:0), PG34:1 (16:0-18:1), PG36:4 (16:0-20:4) and 
PG38:6 (16:0-22:6); (b) were dramatically reduced in Pla2g5-Tg mice compared with WT 
mice. IS, internal standard; (c) RT-PCR of sPLA2-V mRNA in cultured human bronchial 
epithelial  cells  with  or  without  stimulation  for  12  h  with  pro-inflammatory  cytokines. 
sPLA2-V was induced by IL-1 or TNF but not by IFN; (d) A schematic model of the 
role  of  sPLA2-V  in  lung  surfactant  hydrolysis.  sPLA2-V  is  secreted  from  bronchial 
epithelial cells and alveolar macrophages stimulated with pro-inflammatory cytokines, and 
aberrant  hydrolysis  of  surfactant  PC  and  PG  by  sPLA2-V  leads  to  airway  injury.  For 
details, see [8]. 
 
Following  our  study  using  Pla2g5-Tg  mice  as  shown  above,  three  studies  using  mice  null  for 
sPLA2-V (Pla2g5
-/-) by other groups have delineated the crucial contribution of this sPLA2 isoform to 
mouse airway disease models [6,21,22]. Thus, the allergen (ovalbumin or house dust mite)-induced, 
Th2-dependent  asthmatic  models,  as  well  as  the  LPS-induced  ARDS  model,  were  significantly 
reduced in Pla2g5
-/- mice compared with replicate Pla2g5
+/+ mice [6,21]. In the asthmatic models, the 
action of sPLA2-V occurs in two regulatory steps; one at the step of antigen uptake and processing by 
dendritic cells leading to the initiation of the Th2 response, and the other at the step of airway-resident 
cells  which  may  contribute  to  the  propagation  of  airway  inflammation  [22].  The  airway-resident  
cell-dependent pathway requires catalytic activity of sPLA2-V, since aerosolized intake of native, but 
not mutant, sPLA2-V caused a dose-related increase of airway resistance, persistent airway narrowing, 
and  leukocyte  migration,  and  since  intratracheal  application  of  a  neutralizing  antibody  against  
sPLA2-V  ameliorated  the  asthmatic  response  [6].  However,  eicosanoid  levels  in  BALF  were Int. J. Mol. Sci. 2011, 12                       
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unchanged in this model, suggesting that the airway action of sPLA2-V does not profoundly depend on 
lipid  mediators.  Although  the  molecular  mechanism  underlying  the airway-resident  cell-dependent 
pathway has not yet been clarified, we speculate that the protection from disease-associated surfactant 
hydrolysis by the absence of sPLA2-V may be a likely explanation for this event. Thus, blockade of 
endogenous  sPLA2-V  could
  provide  a  potential  new  therapeutic  approach  for  treating  diverse
 
phenotypes of human asthma.  
Studies using Pla2g5
-/- mice have also revealed unique functions of sPLA2-V in inflammation, host 
defense,  and  atherosclerosis.  Pla2g5
-/-  mice  displayed  reduced  zymosan-induced  peritonitis  since 
peritoneal  macrophages  produced  less  eicosanoids  [23],  were  protected  from  Candida  albicans 
infection since phagocytic killing of the fungi by macrophage was reduced [24,25], and were more 
sensitive to inflammatory arthritis since phagocytosis of the pro-inflammatory immune-complex by 
macrophages was reduced in the joints [26]. sPLA2-V can also potently hydrolyze phospholipids in 
low-density (LDL) and high-density (HDL) lipoprotein particles, and LDL receptor-deficient mice 
transplanted  with  Pla2g5
-/-  bone  marrow  cells  are  partially  protected  from  atherosclerosis  
development [27]. Furthermore, a recent single nucleotide polymorphism analysis has revealed an 
association of the human sPLA2-V gene haplotype with plasma LDL levels in patients with type 2 
diabetes [28], suggesting its metabolic role.  
2.2. Group X sPLA2 (sPLA2-X)  
Structurally, sPLA2-X has both the group I- and II-specific properties. Unlike sPLA2-V, which is 
constitutively active once synthesized, sPLA2-X is synthesized as an inactive zymogen and converted 
to an active enzyme by proteolytic removal of the N-terminal propeptide [29]. Amongst the sPLA2 
members, sPLA2-X shows the highest affinity for PC and thereby for the PC-rich outer leaflet in the 
plasma membrane of mammalian cells [30,31]. Accordingly, supplementation or forcible transfection 
of exogenous sPLA2-X results in increased release of arachidonic acid and its oxygenated metabolites 
in many cell types. However, these results should be carefully interpreted, because unlike cPLA2, 
which is ubiquitously expressed and is a central player of arachidonic acid release [1], the expression 
of sPLA2-X is tissue- or cell-specific. In fact, sPLA2-X is constitutively expressed at high levels in the 
genital  and  digestive  organs,  where  they  play  roles  in  sperm  activation  and  gastrointestinal 
phospholipid digestion, respectively, independently of lipid mediator production [32,33]. 
In the lung, sPLA2-X is focally expressed in airway epithelial cells, and its expression is elevated in 
the epithelium as well as in alveolar macrophages following asthmatic challenge in both mice and 
humans [34,35]. The contribution of sPLA2-X to airway inflammation was confirmed by a study using 
mice  lacking  this  enzyme  (Pla2g10
-/-),  in  which  the  ovalbumin-induced,  Th2-dependent  asthmatic 
responses in the airway, including infiltrations of CD4
+ and CD8
+ T cells and eosinophils, mucus 
secretion,  elevation  of  Th2  cytokines,  and  production  of  pro-asthmatic  lipid  mediators  such  as 
cysteinyl leukotrienes and prostaglandin D2 (PGD2), were markedly reduced [34]. Taken together with 
the evidence from Pla2g5
-/- mice (see above), it has become obvious that the two particular sPLA2s, 
sPLA2-V and -X, participate in the asthma pathology. In addition, Pla2g10
-/- mice are protected from 
neutrophil-induced myocardial damage following ischemia-reperfusion, where sPLA2-X is involved in 
the production of leukotriene B4 (LTB4) by neutrophils [36]. Int. J. Mol. Sci. 2011, 12                       
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In order to address the in vivo action of sPLA2-X, we produced transgenic mice overexpressing this 
enzyme in the whole body (Pla2g10-Tg) [8]. Unexpectedly, in contrast to Pla2g5-Tg neonates that 
exhibited  fatal  respiratory  failure  (see  above),  systemic  Pla2g10-Tg  mice  displayed  no  apparent 
abnormality of the respiratory tract with normal alveolar architecture and surfactant composition [8], 
despite the fact that sPLA2-X can potently hydrolyze surfactant PC in vitro [18]. This surprising result 
turned out to be because sPLA2-X protein existed as an inactive zymogen in most tissues. The active 
form of sPLA2-X was produced at inflamed sites in Pla2g10-Tg mice [8]. These results suggest that 
sPLA2-X mostly exists as an inactive zymogen under physiological conditions and that its proteolytic 
activation occurs during inflammation. In contrast, macrophage-specific Pla2g10-Tg mice developed 
severe  lung  inflammation  which  led  to  early  death  by  2~3-weeks  of  age  [37].  Although  the 
discrepancy  between  systemic  and  macrophage-specific  Pla2g10-Tg  mice  is  unclear,  sPLA2-X 
expressed  in  alveolar  macrophages  might  be  efficiently  converted  by proteolytic  processing  to  an 
active form.  
Although  systemic  Pla2g10-Tg  mice  did  not  have  any  alveolar  injury,  we  found  a  remarkable 
phenotype  in  these  mice  before  weaning:  they  developed  alopecia  [38].  Although  pelage  hairs  of 
Pla2g10-Tg mice initially grew, complete but transient hair loss was observed at 3–4 weeks of age, a 
period corresponding to the late stage of the initial hair cycle (Figure 2a). Proteolytic activation of 
sPLA2-X  in  Pla2g10-Tg skin  temporally preceded hair  loss. Histological analyses  of the alopecic 
Pla2g10-Tg  skin  revealed  hair  follicle  distortion,  hyperkeratosis  and  sebaceous  gland  hyperplasia 
(Figure  2b),  which  were  accompanied  by  increased  expression  of  genes  related  to  terminal 
differentiation of epidermis and reduced expression of genes related to hair development. ESI-MS 
analysis of Pla2g10-Tg skin revealed that sPLA2-X hydrolyzed phosphatidylethanolamine (PE), but 
not PC, molecular species to yield PUFAs (Figure 2c), which were further converted to some if not all 
eicosanoids. A schematic model for the action of sPLA2-X in Pla2g10-Tg skin is illustrated in Figure 2d. 
These  results,  together  with  the  finding  that  endogenous  sPLA2-X  shows  a  hair  cycle-dependent 
periodic expression in the outer root sheath of hair follicles in mouse skin (Figure 2e) [38], suggest a 
potential functional link between sPLA2-X and skin biology, and may provide a molecular explanation 
for the skin abnormality induced by aberrant expression of other sPLA2s such as sPLA2-IIA, whose 
transgenic  mice  also  developed  alopecia  [39].  Importantly,  in  Pla2g10
-/-  mice,  hair  growth  in  the 
anagen phase was significantly delayed, and this was caused by growth retardation of the outer root 
sheath in hair follicles [40]. Thus, sPLA2-X intrinsically functions in the hair quality control.  
The ability of sPLA2-X to potently hydrolyze phospholipids in LDL and HDL in vitro has led to the 
hypothesis that, as in the case of sPLA2-V (see above), sPLA2-X may also participate in atherosclerosis. 
Indeed,  sPLA2-X-hydrolyzed  LDL  particles  promote  foam  cell  formation  from  mouse  peritoneal 
macrophages  [41].  These  in  vitro  observations  may  be  relevant  to  cardiovascular  pathology,  since 
Pla2g10
-/-  mice  are  protected  from  angiotensin-II-induced  aortic  aneurysm  and  atherosclerosis  [42]. 
sPLA2-X-released PUFAs negatively regulates liver X receptor (LXR), and accordingly, deficiency of 
sPLA2-X results in augmented LXR activation leading to increased expression of LXR-target genes. 
Thus, in Pla2g10
-/- mice, elevated expression of the ATB-binding cassette (ABC) transporters ABCA1 
and ABCG1 led to increased cholesterol efflux by macrophages [43], that of the steroidogenesis acute 
regulatory protein StAR resulted in increased corticosterone production by adrenal cells [44], and that 
of PPAR (peroxisome proliferator-activated receptor ) facilitated adipogenesis and adiposity [45]. Int. J. Mol. Sci. 2011, 12                       
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On the contrary, Pla2g10
-/- mice maintained on a chow diet over one year gradually lost body weight, 
most likely because dietary phospholipid digestion and thereby lipid absorption in the gastrointestinal 
tract was perturbed [38]. Collectively, these observations have highlighted a novel role of sPLA2-X in 
the regulation of metabolic states.  
Figure 2. Pla2g10-Tg mice display alopecia during the postnatal hair cycle. (a) Pla2g10-Tg 
mice displayed temporary alopecia during 2-3 wk after birth, a period of the postnatal hair 
cycle; (b) Histology of 3-wk-old Pla2g10-Tg mice, in comparison with that of WT mice, 
revealed  hair  follicle  distortion  as  well  as  epidermal  hyperplasia,  sebaceous  gland 
enlargement,  and  cyst  formation;  (c)  ESI-MS  of  skin  phospholipids  indicated  that  PE 
molecular  species  with  PUFA  (arachidonic  acid  (C20:4)  and  docosahexaenoic  acid 
(C22:6)), but not PC, was markedly decreased in Pla2g10-Tg mice compared with WT 
mice; (d) A schematic model of the sPLA2-X action in the skin. sPLA2-X is converted by 
certain skin proteases to its active form, which then hydrolyzes PE in skin membranes to 
liberate  PUFA  that  is  further  metabolized  to  skin-acting  eicosanoids;  (e)  Endogenous 
sPLA2-X is localized in the ORS of hair follicles (shown in red). ORS, outer root sheath; 
IRS, inner root sheath. For details, see [38].  
 
Finally, sPLA2-X is abundantly expressed in testicular spermatigenic cells and is released from the 
acrosome  of  capacitative  (activated)  sperm.  Pla2g10
-/-  spermatozoa  displayed  reduced  acrosome 
reaction  and  thereby  reduced  fertility,  and  this  defect  could  be  restored  by  LPC,  a  potential  
sPLA2-X-generated lipid product [32,38]. sPLA2-X is also expressed in peripheral neurons such as 
dorsal ganglion (DRG) neurons, and DRG from Pla2g10
-/- mice showed reduced, whereas that from 
Pla2g10-Tg  mice  showed  increased,  ex  vivo  neuritogenesis  [38].  Probably  because  of  the  altered Int. J. Mol. Sci. 2011, 12                       
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neuritogenesis,  pain  nociception  in  the  acetic  acid  writhing  test  was  partially  ameliorated  in  
Pla2g10
-/- mice, whereas it was augmented in  Pla2g10-Tg mice, compared with that in littermate 
control mice [38].  
2.3. Group III sPLA2 (sPLA2-III)  
sPLA2-III is the only enzyme belonging to the group III collection. It is an unusually large protein 
(55 kDa) among the sPLA2 family and consists of three domains, in which a central sPLA2 domain 
displaying all the features of group III bee venom sPLA2, including 10 cysteines and the key residues 
of the Ca
2+ loop and catalytic site, is flanked by large and unique N- and C-terminal region [46].  
sPLA2-III is processed to a sPLA2 domain-only form (devoid of the N- and C-terminal domains), 
which is sufficient for its catalytic function [47,48]. sPLA2-III undergoes N-glycosylation and can 
hydrolyze PC and PE equally and augment arachidonate release from cell membranes more efficiently 
than sPLA2-IIA, and less efficiently than sPLA2-X and sPLA2-V. sPLA2-III is immunohistochemically 
detected in the vascular endothelium of various tissues, peripheral and central nervous systems, male 
reproductive  tracts,  and  several  types  of  cancer  [48,49].  Implantation  of  sPLA2-III-transfected 
colorectal  adenocarcinoma  cells  into  nude  mice  promotes  the  growth  of  tumor  xenografts  [48]. 
Expression profiling of the full set of sPLA2s in human colon suggests that sPLA2-III might be a good 
candidate as a novel biomarker for colon cancers [50]. In the central nervous system, Pla2g3 mRNA is 
localized in DRG neurons in mice, and overexpression of human sPLA2-III in cultured neuronal cells 
facilitates  neurite  outgrowth  and  survival  in  correlation  with  the  production  of  LPC,  whereas 
knockdown of endogenous sPLA2-III by siRNA partially suppresses these processes [49]. 
To address the potential in vivo action of sPLA2-III, we produced transgenic mice overexpressing 
this enzyme in the whole body (Pla2g3-Tg). Unlike Pla2g5-Tg mice, which die shortly after birth due 
to a lung disorder resulting from aberrant hydrolysis of the lung surfactant phospholipids (see above), 
Pla2g3-Tg  mice  showed  no  respiratory  disorder,  and  lung  surfactant  phospholipids  did  not  show 
appreciable difference between control and Pla2g3-Tg mice [51]. Furthermore, although Pla2g10-Tg 
mice show alopecia (see above), Pla2g3-Tg mice had normal pelage hairs up to nine months of age. 
Later  on,  however,  Pla2g3-Tg  mice  spontaneously  developed  inflammation  such  as  dermatitis, 
lymphocytic sialadenitis and splenomegaly [51]. The dermatitis was accompanied by hyperkeratosis, 
acanthosis,  parakeratosis,  erosion,  ulcer,  neutrophil  infiltration,  and  increased  production  of 
proinflammatory  cytokines,  chemokines  and  prostaglandin  E2  (PGE2).  It  is  thus  likely  that 
overexpression  of  sPLA2-III  facilitates  the  production  of  pro-inflammatory  lipid  mediators  in  the 
whole body, leading to systemic inflammation. 
To look for potential substrates for sPLA2-III in Pla2g3-Tg mice, lipids extracted from splenocytes 
of  aged  Pla2g3-Tg  and  littermate  control  mice  were  subjected  to  ESI-MS  analysis.  Several  PC 
molecular species were detected in splenocytes of wild-type (WT) mice, and their composition did not 
differ appreciably from those of Pla2g3-Tg mice (Figure 3a, Upper). However, a notable difference 
that could account for the PLA2-mediated lipolysis was seen in PS; of the detectable PS molecular 
species, PS with C18:0-18:1 (m/z = 790.6) were ~50% less in Pla2g3-Tg mice than in control mice 
(Figure 3a, Lower). These results suggest that, in splenocyte membranes, PS with C18:0-18:1 may 
represent a major target substrate of sPLA2-III. Since PS is mainly present in the inner leaflet of the Int. J. Mol. Sci. 2011, 12                       
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plasma membrane of live cells and exposed on apoptotic cell surfaces [52,53], extracellular sPLA2-III 
might  preferentially  hydrolyze  PS  with  C18:0-18:1  on  apoptotic  cells  and  thereby  modulate  the  
life-span of inflammatory cells. In support of this idea, susceptibility of cell membranes to sPLA2s 
increases in apoptotic cells [54]. 
As in  the case of sPLA2-V and -X, sPLA2-III can potently hydrolyze phospholipids in  plasma 
lipoprtein particles [55]. Indeed, the decreased level of plasma lipoproteins, HDL in particular, was 
obvious in Pla2g3-Tg mice in comparison with WT mice (Figure 3b), suggesting HDL hydrolysis by 
overexpressed sPLA2-III. LDL treated with sPLA2-III in vitro was pro-atherogenic, promoting foam 
cell formation from macrophages. When Pla2g3-Tg mice that had been crossed with ApoE
-/- mice 
(Pla2g3
tg/ApoE
-/-) were fed a high-cholesterol diet, lipid accumulation in the aortic walls was markedly 
increased as  compared  with  replicate  ApoE
-/- mice (Figure 3c). Immunohistochemistry and  in situ 
hybridization  revealed  the  presence  of  sPLA2-III  in  human  atherosclerotic  plaques,  particularly  in 
macrophages and smooth muscle cells [55,56]. These results suggest that sPLA2-III may have a role in 
acceleration of atherosclerosis development [55].  
Figure 3. Pla2g3-Tg mice display systemic inflammatory and atherosclerotic phenotypes. 
(a) ESI-MS of PC and PS in splenocytes from Pla2g3-Tg (III-Tg) and wild-type (WT) 
mice. Major peaks are indicated by arrows. Peaks altered in III-Tg mice relative to WT 
mice are shown in red. SM, sphingomyelin; (b) HPLC profile of plasma lipoproteins in  
III-Tg  and  WT  mice;  (c)  Increased  atherosclerosis  in  III-Tg  mice  on  the  ApoE
-/- 
background  (male,  24-wk-old).  Atheroslcerotic  lesions  were  visualized  by  oil  red  
O staining. Areas positive for the staining were quantified. For details, see [51,55]. 
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Figure 4. Pla2g3
-/- mice have multiple defects in epididymal sperm maturation. (a) Altered 
eicosanoid levels in Pla2g3
-/- mice. The levels of individual eicosanoids in the epididymis 
were determined by LC-ESI-MS/MS. sPLA2-III is selectively coupled with 12/15-LOX 
and  CYP450  pathways;  (b)  Unusual  accumulation  of  PC  molecular  species  in  the 
epididymal fluids from Pla2g3
-/- mice relative to Pla2g3
+/+ mice, as assessed by ESI-MS; 
(c) The roles of sPLA2-III in epididymal sperm maturation are summarized. For details,  
see [57]. 
 
 
sPLA2-III is expressed in the testis and epididymis, and in the latter tissue  the mature form of 
sPLA2-III is secreted from the proximal epididymal epithelium into the lumen [57]. We have recently 
succeeded in generating Pla2g3
-/- mice and found that they displayed male infertility [57]. Although 
testicular spermatogenesis in Pla2g3
-/- mice was grossly normal, spermatozoa from the cauda (tail) 
epididymidis displayed hypomotility, and their ability to fertilize intact eggs was markedly impaired. 
Epididymal  spermatozoa  in  Pla2g3
-/-
  mice  had  aberrant  acrosomal  structures  and  flagella  with 
abnormal axonemes. These results revealed an unexplored role of this atypical sPLA2 in epididymal 
lipid homeostasis, whose perturbation led to sperm dysfunction. 
After the complex differentiation process of male germ cells, spermatozoa exit the seminiferous 
tubules of the testis through the efferent ducts toward the epididymis. During their transit from the 
caput  (head)  to  the  cauda  (tail)  epididymidis,  sperm  cells  undergo  significant  morphological  and 
biochemical modifications, which lead to acquisition of their forward motility and ability to recognize 
and fertilize oocytes [58]. Unique to mammalian sperm cells is the abundance of phospholipid species 
with C22-PUFAs, particularly docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), whose 
proportion  in  membrane  phospholipids  appears  to  correlate  with  sperm  maturity,  motility  and  Int. J. Mol. Sci. 2011, 12                       
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fertility [59–62]. The percentage of DHA relative to total fatty acids is correlated with the normal 
morphology of sperm cells [61], and sperm from subfertile men with low sperm motility or counts 
contain a percentage of DHA lower than that from normal men [63]. Sperm maturation involves the 
remodeling of membrane phospholipids toward the acquisition of motility and fertility during sperm 
migration through the epididymis. Indeed, the increase in C22-PUFAs such as DHA and DPA and the 
reciprocal decrease in arachidonic acid (C20:4) favor an increase in the unsaturation degree of fatty 
acids in mouse sperm membrane during epididymal transit [59], which could consequently contribute 
to increasing the mouse sperm membranous fluidity [64,65]. Interestingly, ESI-MS analysis of sperm 
membrane  phospholipids  revealed  that,  during  epididymal  transit,  PC  in  WT  sperm  underwent  a 
dramatic shift in its acyl groups from oleic, linoleic and arachidonic acids to DPA and DHA, whereas 
this  membrane  lipid  remodeling  was  compromised  in  Pla2g3
-/-  sperm  [57].  Accordingly,  cauda 
epididymal spermatozoa in Pla2g3
-/- mice had PC species containing more oleate and less DHA/DPA 
than did those in Pla2g3
+/+ mice, a finding that appears to be consistent with the aforementioned 
notion that sperm with higher DHA percentages have better motility and fertility. Thus, sPLA2-III may 
participate in the hydrolysis of PC with oleic, linoleic and arachidonic acids in the sperm membrane 
during epididymal transit and that this event may be followed by reacylation of LPC, a PLA2 reaction 
product, with DHA and DPA, leading to an increase of PC with DPA/DHA in mature spermatozoa. In 
the Pla2g3
-/- epididymis, impairment of the deacylation step may eventually perturb the subsequent 
reconstitution of DPA/DHA in the sperm membrane, culminating in the asthenozoospermia phenotype. 
We also found a notable change in the ESI-MS/MS profile of lipid mediators in the epididymis of 
Pla2g3
-/- mice [57]. Thus, arachidonate/linoleate metabolites of the 12/15-lipoxygenase (LOX) and 
cytochrome  P450  (CYP450)  pathways,  but  not  those  of  the  cyclooxygenase  (COX)  and  5-LOX 
pathways,  were  substantially  reduced  in  the  epididymis  of  Pla2g3
-/- mice  compared  with  that  of 
Pla2g3
+/+ mice (Figure 4a). Although the role of 12/15-LOX or CYP450 metabolites in male fertility 
has not yet been fully established, expression of 12/15-LOX in spermatogenic cells has led to the 
suggestion that it may participate in sperm maturation [62]. In this context, the possibility that certain 
12/15-LOX- or CYP450-derived lipid mediator(s) may be at least partly responsible for the regulation 
of sperm maturation by sPLA2-III should be taken into account. 
Additionally, sPLA2-III may also affect lipid transport between sperm and epididymal epithelial 
cells. Several lipoprotein components are secreted by epididymal epithelial cells [67] and associate 
with  and  dissociate  from  sperm  membranes  scheduled  for  endocytosis  by  epididymal  principal  
cells [68]. Male fertility can be impaired to various degrees by inactivation of the genes involved in 
lipoprotein  metabolism  [69–71].  In  fact,  membrane  transport  by  epididymosomes,  a  particular 
lipoprotein  membrane  particle  emitted  from  caput  epididymal  principal  cells  into  the  lumen,  is 
fundamental for the process of sperm cell maturation in the epididymis [59,72]. Our speculation that 
sPLA2-III may also affect this epididymal lipid transport is supported by the finding that, as assessed 
by ESI-MS, the epididymal fluid from Pla2g3
-/- mice contained PC more abundantly than that from 
Pla2g3
+/+ mice (Figure 4b). Taken together, we conclude that sPLA2-III may regulate epididymal 
sperm  maturation  through  (i)  regulation  of  phospholipid  remodeling  in  sperm  membranes,  
(ii)  production  of  12/15-LOX  and  CYP450  metabolites,  and  (iii)  modification  of  lipid  transport 
between sperm and epididymal epithelial cells (Figure 4c).  Int. J. Mol. Sci. 2011, 12                       
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2.4. Other sPLA2s: Classical and Novel Enzymes 
Group  IB  pancreatic  sPLA2  (sPLA2-IB)  is  synthesized  in  the  pancreatic  acinar  cells,  and  after 
secretion into the pancreatic juice, an N-terminal heptapeptide of the inactive zymogen is cleaved by 
trypsin to yield an active enzyme in the duodenum [74]. The main role of sPLA2-IB is digestion of 
dietary and biliary phospholipids. Thus, perturbation of this process by gene disruption (Pla2g1b
-/-) or 
pharmacological  inhibition  of  sPLA2-IB  led  to  protection  from  diet-induced  obesity  and  insulin 
resistance  due  to  decreased  lipid  digestion  and  absorption  in  the  gut  [75,76].  In  agreement,  the 
PLA2G1B gene resides within a locus for obesity susceptibility in humans [77]. 
Group IIA sPLA2 (sPLA2-IIA) is often referred to as an inflammatory sPLA2, since its expression is 
markedly  induced  during  inflammation,  cardiovascular  diseases,  and  tissue  damages  [78].  When 
overexpressed, sPLA2-IIA is capable of augmenting arachidonic acid release in cytokine-stimulated 
cells, albeit more weakly than sPLA2-V, -X and -III [79]. Despite these facts, the contribution of 
sPLA2-IIA to inflammation has remained a subject of debate until recently, since a natural mutation of 
its gene in C57BL/6 and 129Sv mice [80] prevents the proper assessment of its functions by a classical 
gene targeting strategy. Intrinsic deficiency of sPLA2-IIA in these mouse strains is associated with 
increased incidence of intestinal polyposis and tumorigengesis [80], a phenotype that is reversed by 
transgenic expression of the Pla2g2a gene [81]. A recent study using Pla2g2a-deficient BALB/c mice 
as well as Pla2g2a-Tg mice has provided compelling evidence that the enzyme plays an exacerbating 
role  in  inflammatory  arthritis  [26].  The  best-recognized  physiologic  function  of  sPLA2-IIA  is  the 
degradation of Gram-positive bacterial membrane, thereby providing the first line of antimicrobial defense 
of the host [82–85]. The serum level of sPLA2-IIA also shows correlation with the risk of cardiovascular 
diseases [86], and Pla2g2a-Tg mice fed an atherogenic diet developed atherosclerosis [87,88]. This effect 
is probably because sPLA2-mediated hydrolysis of LDL phospholipids leads to generation of small-
dense, pro-atherogenic LDL particles that facilitate macrophage foam cell formation, even though the 
hydrolytic activity of sPLA2-IIA toward lipoportein particles is much weaker than that of sPLA2-V, -X 
and -III. Pla2g2a-Tg mice also displayed permanent alopecia and were susceptible to carcinogen-
induced skin tumorigenesis [39,40]. 
The roles of other group II subfamily sPLA2 isoforms remain elusive, since knockout or transgenic 
mice for these enzymes have not yet been reported. sPLA2-IIC is expressed in rodent testis, but not in 
humans [89]. sPLA2-IID is structurally most similar to sPLA2-IIA, and its transcript is constitutively 
detected in the lymphoid organs [90]. This enzyme may have immuno-suppressive functions, since it is 
expressed in regulatory T cells and its fusion protein has the ability to suppress inflammatory bowel 
disease  and  experimental  autoimmune  encephalomyelitis  in  mice  [91].  sPLA2-IIE,  another  group  
IIA-related  enzyme,  is  expressed  constitutively  in  several  tissues  at  low  levels  and  has  a  lower 
catalytic  activity  than  other  group  II  sPLA2s  [92].  sPLA2-IIF  possesses  a  unique  30-amino  acid  
C-terminal extension that contains an additional Cys residue, which might contribute to formation of a 
homodimer or a heterodimer with a second protein [93,94]. This enzyme is expressed most abundantly 
in the skin [100].  
Lastly, group XII sPLA2s (sPLA2-XIIA and -XIIB) represent a unique collection of the sPLA2 
family. sPLA2-XIIA has the central catalytic domain with a His/Asp catalytic dyad, yet the location of 
Cys  residues  outside  the  catalytic  domain  is  rather  distinct  from  that  of  other  sPLA2s  [95]. High Int. J. Mol. Sci. 2011, 12                       
 
 
1487 
expression of this enzyme is found in many tissues, although its enzymatic activity is very weak. A 
study using Xenopus suggests the role of this enzyme in early neuronal development [96]. sPLA2-XIIB 
is structurally related to sPLA2-XIIA and is expressed in liver and intestine [97]. A recent study has 
demonstrated that the transcription of Pla2g12b was regulated by the transcription factor HNF-4 and 
its co-activator PGC-1, and deletion of the Pla2g12b gene resulted in increased fat accumulation in 
the liver leading to steatohepatitis, a phenotype similar to that seen in Hnf4a
-/- mice [98]. The aberrant fat 
accumulation in Pla2g12b
-/- liver was ascribed to impaired hepatic secretion of VLDL. However, because 
sPLA2-XIIB lacks the catalytic activity since the catalytic center His is replaced with Leu [97], the 
molecular mechanism whereby this sPLA2 isoform regulates VLDL secretion remains unknown. 
3. Conclusions 
During the past decade, the biological functions of several sPLA2s and their target substrates have 
been  clarified  by  studies  using  transgenic  and  knockout  mice  in  combination  with  lipidomics. 
Nevertheless, full understanding of the biological roles of all sPLA2 isoforms is still a challenging area 
of research. The control of particular sPLA2s, alone or in combination of multiple isoforms, should 
have advantages over the inhibition of selective lipid metabolic pathways in the treatment of various 
diseases. Interestingly, the pan-sPLA2 inhibitor A-002 (varespladib), which inhibits the conventional 
class of sPLA2s, can markedly reduce the atherosclerotic lesion area in experimental animals and even 
in humans in early-phase clinical studies [99]. This fact points to the sPLA2 family as a potential 
therapeutic target for atherosclerosis, and probably other diseases in which one or more sPLA2s are 
involved, such as asthma, arthritis, and metabolic syndrome.  
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